Janssen Pharmaceuticals wins FDA approval for Erleada(apalutamide) Tablets for the treatment of Prostate Cancer

 FDA approves Erleada Tablets for the treatment of Prostate Cancer

A new drug that can stall the progression of a particularly hard-to-treat form of prostate cancer has been approved for use by U.S. health officials.

Company: Janssen Pharmaceuticals, Inc.

Brand Name: Erleada

Generic Name: apalutamide

Dosage Form: Tablets

Treatment For: Prostate Cancer




General information about Erleada

Erleada (apalutamide) is an oral androgen receptor inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC).

Erleada (apalutamide) has shown breakthrough effectiveness in keeping prostate cancer from spreading for two years in men whose disease had not yet traveled to other parts of their body